Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Apr 1;51(4):409-415.
doi: 10.1097/DSS.0000000000004480. Epub 2024 Oct 24.

Exosomes for Treating Hair Loss: A Review of Clinical Studies

Dawn Queen  1 , Marc R Avram  2
Affiliations
Review

Exosomes for Treating Hair Loss: A Review of Clinical Studies

Dawn Queen et al. Dermatol Surg. .

Abstract

Background: The regenerative properties of exosomes make them especially appealing to treat skin and hair diseases. Preclinical studies suggest that exosomes may fuel hair growth by stimulating dermal papilla cells, activating hair follicle stem cells, and promoting angiogenesis. However, very limited data are available on the safety and efficacy of exosome use in human subjects.

Objective: To review the published literature on exosome use in human subjects with a focus on safety and the challenges facing clinical implementation in the treatment of androgenetic and nonscarring alopecias.

Materials and methods: A review was conducted of PubMed, EMBASE, and Cochrane databases and included 48 studies. Twenty-five studies were clinical trials, 14 case reports, 4 case series, 1 retrospective review, and 4 conference abstracts.

Results: Nine clinical studies were found relevant to alopecia. One hundred twenty-five patients received an exosome treatment for hair loss. Side effects were rare. However, in the broader field of dermatology, at least 10 serious adverse events have been reported.

Conclusion: Although exosomes have many promising therapeutic applications, there is demand for larger well-designed clinical trials with extended follow-up periods to prove efficacy and a need for consistent manufacturing standards and regulatory oversight to ensure product safety.

PubMed Disclaimer

References

    1. Xiong M, Zhang Q, Hu W, Zhao C, et al. The novel mechanisms and applications of exosomes in dermatology and cutaneous medical aesthetics. Pharmacol Res 2021;166:105490.
    1. Kordelas L, Rebmann V, Ludwig AK, Radtke S, et al. MSC-derived exosomes: a novel tool to treat therapy-refractory graft-versus-host disease. Leukemia 2014;28:970–3.
    1. Zhou L, Wang H, Jing J, Yu L, et al. Regulation of hair follicle development by exosomes derived from dermal papilla cells. Biochem Biophys Res Commun 2018;500:325–32.
    1. FDA. Public Safety Notification on Exosome Products. U.S. Food and Drug Administration; 2019. Available at: https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologi... . Accessed September 4, 2024.
    1. Morse MA, Garst J, Osada T, Khan S, et al. A phase I study of dexosome immunotherapy in patients with advanced non-small cell lung cancer. J Transl Med 2005;3:9.

LinkOut - more resources